Quantitative benefit-risk modelling of infliximab biosimilar inflectra versus reference product remicade in the treatment of Crohn's disease

被引：0
|
作者：
Catt, Heather [1 ]
Hughes, Dyfrig [2 ]
Bodger, Keith [1 ]
Kirkham, Jamie [1 ]
机构：
[1] Univ Liverpool, Liverpool, Merseyside, England
[2] Univ Bangor, Bangor, Gwynedd, Wales
来源：
TRIALS | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
P143
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease
    Heather Catt
    Keith Bodger
    Jamie J. Kirkham
    Dyfrig A. Hughes
    PharmacoEconomics, 2019, 37 : 1509 - 1523
  • [2] Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease
    Catt, Heather
    Bodger, Keith
    Kirkham, Jamie J.
    Hughes, Dyfrig A.
    PHARMACOECONOMICS, 2019, 37 (12) : 1509 - 1523
  • [3] QUANTITATIVE BENEFIT-RISK MODELLING OF BIOSIMILARS: A CASE STUDY OF INFLIXIMAB IN CROHN'S DISEASE.
    Catt, H.
    Bodger, K.
    Kirkham, J.
    Hughes, D. A.
    VALUE IN HEALTH, 2018, 21 : S380 - S380
  • [4] Remicade (infliximab) for the treatment of Crohn's disease
    Brazier, F
    Delcenserie, R
    Dupas, JL
    PRESSE MEDICALE, 2000, 29 (26): : 1463 - 1464
  • [5] Comparative analysis of the pharmacokinetics of Inflectra® biosimilar with Remicade® in the induction phase of remission in patients with Crohn's disease
    Juan, G.
    Mora, M.
    Alvarino, A.
    Maroto, N.
    Ferrer, I.
    Hinojosa, E.
    Hinojosa, M. D.
    Ferrandis, P.
    Hinojosa, J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S403 - S403
  • [6] Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease
    Baldassano, R
    Braegger, CP
    Escher, JC
    DeWoody, K
    Hendricks, DF
    Keenan, GF
    Winter, HS
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (04): : 833 - 838
  • [7] Infliximab (Remicade™), a new biological treatment for Crohn's disease
    D'Haens, GR
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 31 (06): : 519 - 520
  • [8] Treatment Benefit-Risk Preferences of Patients with Early Crohn's Disease
    Loftus, Edward
    Yang, Mei
    Skup, Martha
    Ivanova, Jasmina
    Sorg, Rachael
    Chao, Jingdong
    Mulani, Parvez
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S642 - S642
  • [9] ABP 710, a Biosimilar to Infliximab Reference Product: Supporting Extrapolation of Indications With a Focus on Crohn's Disease
    Reinisch, Walter
    Halder, Smita
    Khan, Waliul I.
    Wang, Xuanyu
    Kuhns, Scott
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1678 - S1679
  • [10] Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn's disease
    Puli, SR
    Benage, DD
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (04): : 939 - 940
12345